CCN(C(C)C)C(C)C.[OH:10][C:11]1[CH:16]=[CH:15][CH:14]=[CH:13][C:12]=1[C:17]1[NH:21][N:20]=[C:19]([C:22]([OH:24])=O)[CH:18]=1.CCN=C=NCCCN(C)C.C1C=CC2N(O)N=NC=2C=1.[NH2:46][CH2:47][C:48]([N:50]1[CH2:55][CH2:54][N:53]([C:56](=[O:65])[C:57]2[CH:62]=[C:61]([Cl:63])[CH:60]=[CH:59][C:58]=2[Cl:64])[CH2:52][CH2:51]1)=[O:49].Cl>CN(C=O)C.O>[Cl:64][C:58]1[CH:59]=[CH:60][C:61]([Cl:63])=[CH:62][C:57]=1[C:56]([N:53]1[CH2:52][CH2:51][N:50]([C:48](=[O:49])[CH2:47][NH:46][C:22]([C:19]2[CH:18]=[C:17]([C:12]3[CH:13]=[CH:14][CH:15]=[CH:16][C:11]=3[OH:10])[NH:21][N:20]=2)=[O:24])[CH2:55][CH2:54]1)=[O:65]DIPEA (170.4 mg, 0.23 mL, 1.3 mmol) was added drop wise to 5-(2-Hydroxy-phenyl)-1H-pyrazole-3-carboxylic acid (prepared by the method as described above) (60 mg, 0.29 mmol) in DMF (2 mL). EDCI (140.4 mg, 0.73 mmol) and HOBT (43.6 mg, 0.32 mmol) were then added. After 2 minutes, 2-Amino-1-[4-(2,5-dichloro-benzoyl)-piperazin-1-yl]-ethanone in its HCl salt form (113.9 mg, 0.32 mmol) was added. The resulting mixture was stirred at room temperature overnight. Cold water was then added and the product was extracted with EtOAc and the organic layer was washed with brine. The organic phase was dried over Na2SO4 and concentrated under reduced pressure to get the residue purified by column chromatography (using silica gel of 60-120 mesh and 10% MeOH in CHCl3 as eluent) to afford 28 mg (20% yield) of 5-(2-hydroxy-phenyl)-1H-pyrazole-3-carboxylic acid {2-[4-(2,5-dichloro-benzoyl)-piperazin-1-yl]-2-oxo-ethyl}-amide. LCMS Purity: 97.07%. 1H NMR (DMSO-d6): δ 13.3 (s, 1H), 10.3 (s, 1H), 8.0 (t, 1H), 7.8-7.4 (m, 4H), 7.28-7.1 (t, 1H), 7.1-7.05 (s, 1H), 7.02-6.8 (m, 2H), 4.3-4.1 (d, 2H), 3.8-3.6 (m, 4H), 3.55-3.42 (s, 2H), 3.3-3.1 (m, 3H).
Loading…